glp-1 receptor agonist medicines Agonists: A Comprehensive Overview Discovery of GLP-1–Based Drugs for

CDCA, chenodeoxycholic acid

They were found to have significant HbA1c, and weight reduction compared to placebo in patients with diabetes and obesity respectively

It is majorly found circulating in the blood as GLP-1(7-36) amide that is produced primarily from three tissues of the human body: enteroendocrine L cells in the distal small bowel, cells in the pancreas, and the central nervous system ( Surprisingly, it took approximately 20 years from the discovery of GLP-1 to the authorized approval of worldwide utilized GLP-1 RAs

Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effectsincluding anti-inflammatory, antioxidant, and neuroprotective propertiesthat position them as transformative candidates for ocular therapeutics

Moreover, rare post-marketing reports of pruritus, urticaria, and angioneurotic edema have been described with exenatide, liraglutide, and lixisenatide [48, 104, 105]

My concern is that we dont know where that somewhere else is..yet